What's new? Log in Free sign up

Sanofi (SNY)

Company Profile

Company profile

Ticker

SNY, SNYNF

Exchange

Website

CEO

Mr. Paul Hudson

Incorporated

Location

Fiscal year end

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co. • Teva Pharmaceutical Industries Limited • Abbott Laboratories • Eli Lilly and • Bristol-Myers Squibb • Viatris • AbbVie • Bausch Health Companies ...

Former names

SANOFI SYNTHELABO SA, SANOFI-AVENTIS

SEC CIK

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Material Contracts & Credit Agreements

Subsidiaries Lists

IRS number

133529324

SNY stock data

1M 3M 6M 1Y

Latest filings (excl ownership)

View all

Dupixent sBLA accepted for FDA priority review for the targeted treatment of bullous pemphigoid

Disclosure regarding Iran Threat Reduction and Syria Human Rights Act

Annual report (foreign)

Update on extraintestinal pathogenic E. coli vaccine phase 3 clinical study

Execution of a share buyback agreement for up to €2 billion

Current report (foreign)

Current report (foreign)

Current report (foreign)

New Sarclisa subcutaneous formulation met co-primary endpoints in the IRAKLIA phase 3 study in multiple myeloma

Current report (foreign)

Transcripts

View all

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Earnings call transcript

Latest ownership filings

View all

Quarterly holdings report by institutional manager

MeiraGTx Holdings plc

MeiraGTx Holdings plc

Annual report of employee stock purchases

Annual report of employee stock purchases

Inhibrx Biosciences, Inc.

Financial summary

Financial statements Chart SNY financial data

Quarter (USD)	Dec 24	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 24	Dec 22	Dec 21	Dec 20
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from Sanofi earnings reports.

Institutional ownership, Q4 2024

SNY institutional ownership history Ownership history

10.5% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	694	736	-5.7%
Opened positions	73	90	-18.9%
Closed positions	115	66	+74.2%
Increased positions	241	289	-16.6%
Reduced positions	269	227	+18.5%

13F shares	Current	Prev Q	Change
Total value	11.78 tn	15.19 tn	-22.4%
Total shares	263.61 mm	277.89 mm	-5.1%
Total puts	1.32 mm	1.57 mm	-16.3%
Total calls	1.79 mm	1.97 mm	-9.1%
Total put/call ratio	0.7	0.8	-7.8%

Largest owners	Shares	Value	Change
Dodge & Cox	75.22 mm	$3.63 tn	-1.4%
Fisher Asset Management	12.51 mm	$603.41 bn	-6.3%
IVZ Invesco	12.06 mm	$581.62 bn	+3.5%
BAC Bank of America	12.02 mm	$579.59 bn	+3.8%
T. Rowe Price	10.84 mm	$522.99 mm	+88.5%
MS Morgan Stanley	10.08 mm	$486.39 bn	-43.3%
Barrow Hanley Mewhinney & Strauss	7.70 mm	$371.24 bn	-1.8%
BlackRock	7.69 mm	$370.91 bn	-25.6%
Boston Partners	5.40 mm	$260.61 bn	+86.4%
FMR	4.96 mm	$239.38 bn	-42.4%

Largest transactions	Shares	Bought/sold	Change
MS Morgan Stanley	10.08 mm	-7.69 mm	-43.3%
BK The Bank of New York Mellon Corporation	2.79 mm	-6.53 mm	-70.1%
T. Rowe Price	10.84 mm	+5.09 mm	+88.5%
FMR	4.96 mm	-3.65 mm	-42.4%
Mondrian Investment Partners	3.45 mm	+3.45 mm	NEW
Raymond James & Associates	0.00	-2.82 mm	EXIT
RJF Raymond James Financial	2.82 mm	+2.82 mm	NEW
BlackRock	7.69 mm	-2.65 mm	-25.6%
Boston Partners	5.40 mm	+2.50 mm	+86.4%
Millennium Management	295.18 k	-2.45 mm	-89.2%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

News

From Benzinga Pro

FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes

Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.

Regeneron And Sanofi Announce FDA Priority Review For Dupixent In Bullous Pemphigoid, With Approval Decision Expected By June 2025

If approved, Dupixent would be the first and only targeted medicine to treat BP in the U.S.; FDA decision expected by June 20, 2025Priority Review granted based on positive pivotal results demonstrating significant

How Is The Market Feeling About Sanofi?

U.S. CDC Report: Evidence Found Of Recent Bird Flu Infections Among 3 Cattle Veterinarians

Sanofi/Johnson & Johnson Partnered Vaccine Against Bacterial Sepsis Flunks Late-Stage Study

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.